Skip to content
HowShorted

Sarepta Therapeutics, Inc. short interest in 2021

In 2021, Sarepta Therapeutics, Inc.'s disclosed short interest ran from 10.26% of shares outstanding on 15 Jan 2021 to 5.26% on 31 Dec 2021, a change of -5.00 percentage points. The year's high was 10.26% on 15 Jan 2021 and its low 5.26% on 31 Dec 2021, averaging 7.88% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.38 days on 30 Apr 2021. Full history: Sarepta Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Sarepta Therapeutics, Inc. in 2021

2021 in figures

Start of year
10.26% (15 Jan 2021)
End of year
5.26% (31 Dec 2021)
Change
-5.00 pp
High
10.26% (15 Jan 2021)
Low
5.26% (31 Dec 2021)
Average
7.88%
Highest days to cover
11.38 (30 Apr 2021)
SEC filings marked
6

Every report in 2021

Sarepta Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202110.26%1.35results (8-K)
29 Jan 20219.82%4.07
12 Feb 20218.51%6.65
26 Feb 20219.27%5.54
15 Mar 20218.64%6.5210-K filed
31 Mar 20219.27%6.83
15 Apr 20219.21%8.95
30 Apr 20218.91%11.38
14 May 20219.62%5.5010-Q filed
28 May 202110.02%4.77
15 Jun 20218.34%5.85
30 Jun 20218.07%8.04
15 Jul 20218.14%8.63
30 Jul 20217.92%8.54
13 Aug 20217.75%7.1410-Q filed
31 Aug 20217.35%8.25
15 Sep 20217.09%8.68
30 Sep 20216.31%5.40
15 Oct 20216.30%3.13results (8-K)
29 Oct 20215.27%4.81
15 Nov 20215.37%4.8110-Q filed
30 Nov 20216.26%6.50
15 Dec 20216.19%6.32
31 Dec 20215.26%6.28

See also: Sarepta Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.